- Home
- NN vs PRCT Comparison
NN vs PRCT Comparison
Compare NN & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NN | PRCT |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NN | PRCT |
|---|---|---|
| Price | $14.40 | $28.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $51.13 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 03-11-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,539,000.00 | ★ $299,907,000.00 |
| Revenue This Year | N/A | $48.30 |
| Revenue Next Year | N/A | $29.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 11.61 | ★ 50.07 |
| 52 Week Low | $9.05 | $27.80 |
| 52 Week High | $18.25 | $75.29 |
Technical Indicators
Market Signals| Indicator | NN | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 38.93 |
| Support Level | $14.13 | $28.76 |
| Resistance Level | $17.85 | $31.35 |
| Average True Range (ATR) | 1.15 | 1.52 |
| MACD | -0.12 | -0.17 |
| Stochastic Oscillator | 13.27 | 7.94 |
Price Performance
Historical ComparisonAbout NN NextNav Inc.
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.